Trials / Withdrawn
WithdrawnNCT00477217
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee
A Randomized, Double-blind, Placebo-controlled, Proof of Concept Study of Zoledronic Acid in Spontaneous Osteonecrosis of the Knee (SONK)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- —
Summary
This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2007-05-23
- Last updated
- 2016-09-23
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00477217. Inclusion in this directory is not an endorsement.